Abbott Laboratories
Financials
Valuation Metrics
Abbott Laboratories's Market Cap is $186.64B. At end of 2025 it was $217.77B. Ranked #79 of 3,112 in US market (top 3%), #49 of 1,667 on NYSE (top 3%), #3 of 206 in Health Care Equipment & Services (top 1%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $186.64B | US#79/3,112 Sec#3/206 |
| Revenue | $46.59B | US#150/3,112 Sec#11/206 |
| Net Income | $5.42B | US#131/3,112 Sec#5/206 |
| Total Assets | $109.22B | US#167/3,112 Sec#6/206 |
| Net Assets | $51.11B | US#93/3,112 Sec#5/206 |
| Employees | 115,000 | US#64/3,112 Sec#5/206 |
| Value | ||
| P/E | 34.40x | US#1,576/3,112 Sec#61/206 |
| P/B | 3.65x | US#1,888/3,112 Sec#114/206 |
| P/S | 4.01x | US#2,073/3,112 Sec#143/206 |
| EV/EBITDA | 21.54x | US#1,933/3,112 Sec#92/206 |
| FCF Yield | 4.67% | US#1,351/3,112 Sec#72/206 |
| Profitability | ||
| ROE | 10.61% | US#1,296/3,112 Sec#61/206 |
| ROA | 4.97% | US#1,005/3,112 Sec#64/206 |
| Op. Margin | 17.03% | US#1,111/3,112 Sec#40/206 |
| Revenue Growth | 13.02% | US#1,076/3,112 Sec#75/206 |
| Earnings Growth | -47.84% | US#1,848/3,112 Sec#94/206 |
| Financial Health | ||
| Debt Ratio | 112.41% | US#1,201/3,112 Sec#117/206 |
| Total Debt | $32.61B | US#145/3,112 Sec#5/206 |
| FCF | $8.72B | US#94/3,112 Sec#4/206 |
| Cash | $5.10B | US#193/3,112 Sec#8/206 |
| Current Ratio | 1.38x | US#1,794/3,112 Sec#161/206 |
| Net Debt/EBITDA | 2.77x | US#1,593/3,112 Sec#95/206 |
| Dividend | ||
| Div. Yield | 2.28% | US#820/3,112 Sec#13/206 |
| Div. Growth | 6.36% | US#707/3,112 Sec#28/206 |
| Performance | ||
| 1Y Return | -15.02% | US#2,510/3,112 Sec#164/206 |
| 1M Return | 12.32% | US#400/3,112 Sec#38/206 |
| From 52W High | -21.32% | US#1,782/3,112 Sec#123/206 |
| 1Y MDD | -39.37% | US#1,918/3,112 Sec#104/206 |
| Trading | ||
| Volume | 4,766,729 shares | US#388/3,112 Sec#17/206 |
| Trading Value | $513M | US#209/3,112 Sec#11/206 |
| Per Share | ||
| EPS | $3.73 | US#829/3,112 Sec#49/206 |
| BPS | $29.84 | US#868/3,112 Sec#52/206 |
Company Info
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.